HCPCS Level II code J0132 represents a 100 mg injectable dose of acetylcysteine, used clinically as a mucolytic and as an antidote in certain toxic ingestions. Nationally, this code matters for hospital outpatient departments, emergency departments, and infusion centers because it captures billing for a commonly administered parenteral medication with specific dosing units. Appropriate coding affects drug utilization tracking, cost reporting, and payer reimbursement for infusion services.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding context, common billing practices, and typical sites of service. The publication provides benchmarks where available, clarifies clinical use cases tied to injectable acetylcysteine, and summarizes relevant policy considerations that influence coverage and billing for injectable medications at the national level.

This summary is intended to orient clinicians, billing professionals, and policy analysts to the primary purpose of J0132, the settings in which it is billed, and the payer landscape relevant to national reimbursement and utilization discussions. Data not available in the input will be flagged within the full publication.